Clinical Trial

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Name: Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma — clinical trial record (NCT07601607)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a phase 1b/2a, open-label trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of lisaftoclax in combination with chidamide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Trial Details

NCT Number	NCT07601607
Lead Sponsor	Sun Yat-sen University
Conditions	Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Enrollment	51 participants
Start Date	2026-05-30
Primary Completion	2028-05-30 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-22